KORU Medical Systems, Inc. (KRMD) CFO granted 75,000 RSUs equity award

Q: How many RSUs did the KORU Medical (KRMD) CFO receive and at what price?

The CFO received 75,000 RSUs $0 per unit

Q: What is the vesting schedule for the 75,000 RSUs granted to the KORU Medical CFO?

One-fourth of the award will vest on January 2, 2027

Q: What does each restricted stock unit granted by KORU Medical represent?

Each RSU represents a contingent right to receive one share of KORU Medical Systems, Inc. common stock

Q: Under which plan were the KORU Medical CFO’s RSUs issued?

The 75,000 RSUs 2024 Omnibus Equity Incentive Plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

KORU Medical Systems, Inc. granted its Chief Financial Officer, Thomas Adams, an award of 75,000 restricted stock units (RSUs)

One-fourth of the RSUs will vest on January 2, 202775,000 derivative securities$0 per unit

Positive

None.

Negative

None.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Adams Thomas Edward

Role Chief Financial Officer

Type Security Shares Price Value

Grant/Award Restricted Stock Units 75,000 $0.00 --

Holdings After Transaction: Restricted Stock Units — 75,000 shares (Direct)

Footnotes (1)

Each restricted stock unit was issued pursuant to the Company's 2024 Omnibus Equity Incentive Plan and represents a contingent right to receive one share of common stock of KORU Medical Systems, Inc. (the "Company") upon vesting. One-fourth will vest on January 2, 2027 and on each first, second and third anniversary thereof or upon an earlier change in control of the Company.

Form 4 Insider Transactions: What Each Field Means →

01/06/2026 - 04:05 PM

SEC Form 4

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*
Adams Thomas Edward

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)
MAHWAH NJ 07430

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director 10% Owner

X Officer (give title below) Other (specify below)

Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)

Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Restricted Stock Units ⁽¹⁾ 01/02/2026 A 75,000 ⁽²⁾ ⁽²⁾ Common Stock 75,000 $0 75,000 D

Explanation of Responses:

1. Each restricted stock unit was issued pursuant to the Company's 2024 Omnibus Equity Incentive Plan and represents a contingent right to receive one share of common stock of KORU Medical Systems, Inc. (the "Company") upon vesting.

2. One-fourth will vest on January 2, 2027 and on each first, second and third anniversary thereof or upon an earlier change in control of the Company.

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.

/s/ Thomas Adams 01/06/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did KORU Medical (KRMD) report for its CFO?

KORU Medical Systems, Inc. reported that Chief Financial Officer Thomas Adams75,000 restricted stock units (RSUs)January 2, 2026

How many RSUs did the KORU Medical (KRMD) CFO receive and at what price?

The CFO received 75,000 RSUs$0 per unit

What is the vesting schedule for the 75,000 RSUs granted to the KORU Medical CFO?

One-fourth of the award will vest on January 2, 2027

What does each restricted stock unit granted by KORU Medical represent?

Each RSU represents a contingent right to receive one share of KORU Medical Systems, Inc. common stock

How many derivative securities does the KORU Medical CFO hold after this RSU grant?

After the reported transaction, Chief Financial Officer Thomas Adams beneficially owns 75,000 derivative securitiesdirect ownership

Under which plan were the KORU Medical CFO’s RSUs issued?

The 75,000 RSUs2024 Omnibus Equity Incentive Plan

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	01/02/2026		A		75,000		⁽²⁾	⁽²⁾	Common Stock	75,000	$0	75,000	D

	/s/ Thomas Adams	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.